Invention Grant
- Patent Title: Anti-cancer agent comprising HVJ-E and CXCL2
-
Application No.: US15754687Application Date: 2016-08-23
-
Publication No.: US10441613B2Publication Date: 2019-10-15
- Inventor: Yasufumi Kaneda , Toshihiro Nakajima
- Applicant: OSAKA UNIVERSITY , GenomIdea Inc.
- Applicant Address: JP Suita JP Osaka
- Assignee: OSAKA UNIVERSITY,GenomIdea Inc.
- Current Assignee: OSAKA UNIVERSITY,GenomIdea Inc.
- Current Assignee Address: JP Suita JP Osaka
- Agency: Leydig, Voit & Mayer, Ltd.
- Priority: JP2015-164600 20150824
- International Application: PCT/JP2016/074464 WO 20160823
- International Announcement: WO2017/033912 WO 20170302
- Main IPC: A61K39/00
- IPC: A61K39/00 ; A61K48/00 ; C12Q1/68 ; A61K38/00 ; A61K35/76 ; A61K38/19 ; A61K45/00 ; A61K31/7088 ; A61K31/713 ; A61K31/739 ; A61P35/00 ; C12N7/00
Abstract:
The present invention provides, as a new anti-cancer agent obtained by combining HVJ-E and a molecule synergistically acting therewith, an anti-cancer agent containing the following (1) and (2): (1) HVJ-E (hemagglutinating virus of Japan envelope), (2) CXCL2, a nucleic acid comprising a base sequence encoding CXCL2 or a CXCL2 expression inducing agent.
Public/Granted literature
- US20180243355A1 ANTI-CANCER AGENT COMPRISING HVJ-E AND CXCL2 Public/Granted day:2018-08-30
Information query
